Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

EBioMedicine

Volumn 2, Issue 3, 2015, Pages 264-271

  Mendell, Jeanne ^a   Freeman, Daniel J ^a   Feng, Wenqin ^a   Hettmann, Thore ^b,e   Schneider, Matthias ^b   Blum, Sabine ^b   Ruhe, Jens ^b   Bange, Johannes ^b   Nakamaru, Kenji ^c   Chen, Shuquan ^a   Tsuchihashi, Zenta ^a   von Pawel, Joachim ^d   Copigneaux, Catherine ^a   Beckman, Robert A ^a,f  

^a DAIICHI SANKYO INC   (United States)

^b U3 Pharma GmbH   (Germany)

^c DAIICHI SANKYO CO   (Japan)

^d Asklepios Fachkliniken   (Germany)

^e BioVille   (Belgium)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

Biomarker; Erlotinib; HER3; Heregulin; Non small cell lung cancer; Patritumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PATRITUMAB; PLACEBO; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NRG1 PROTEIN, HUMAN; TUMOR MARKER; U3-1287;

ADVANCED CANCER; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUREGULIN-1; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RETROSPECTIVE STUDIES; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84946099956     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.02.005     Document Type: Article

References (58)

1. al Moustafa A.E., Alaoui-Jamali M., Paterson J., O'Connor-McCourt M. Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. Anticancer Res. 1999, 19:481-486.
2. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997, 410:83-86.
3. Altman D.G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst. 1994, 86:829-835.
4. Atlas E., Cardillo M., Mehmi I., Zahedkargaran H., Tang C., Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol. Cancer Res. 2003, 1:165-175.
5. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
6. Beckman R.A., Clark J., Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat. Rev. Drug Discov. 2011, 10:735-748.
7. Carraway K.L., Sliwkowski M.X., Akita R., Platko J.V., Guy P.M., Nuijens A., Diamonti A.J., Vandlen R.L., Cantley L.C., Cerione R.A. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem. 1994, 269:14303-14306.
8. de Alava E., Ocaña A., Abad M., Montero J.C., Esparís-Ogando A., Rodriguez C.A., Otero A.P., Hernández T., Cruz J.J., Pandiella A. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J. Clin. Oncol. 2007, 25:2656-2663.
9. Freeman D., Ogbagabriel S., Rothe M., Radinsky R., Treder M. Fully human anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors. AACR Meeting Abstracts 2008, LB-21.
10. Freeman D., Ogbagabriel S., Schneider M., Radinsky R., Hettman T. U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in NSCLC models. Mol. Cancer Ther. 2009, 8:B171.
11. Fridlyand J., Simon R.M., Walrath J.C., Roach N., Buller R., Schenkein D.P., Flaherty K.T., Allen J.D., Sigal E.V., Scher H.I. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat. Rev. Drug Discov. 2013, 12:743-755.
12. Garrett J.T., Olivares M.G., Rinehart C., Granja-Ingram N.D., Sánchez V., Chakrabarty A., Dave B., Cook R.S., Pao W., McKinely E., Manning H.C., Chang J., Arteaga C.L. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5021-5026.
13. Gullick W.J. The c-erbB3/HER3 receptor in human cancer. Cancer Surv. 1996, 27:339-349.
14. Hall J.A., Salgado R., Lively T., Sweep F., Schuh A. A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. Lancet Oncol. 2014, 15:e184-e193.
15. Hegde G.V., de la Cruz C.C., Chiu C., Alag N., Schaefer G., Crocker L., Ross S., Goldenberg D., Merchant M., Tien J., Shao L., Roth L., Tsai S.P., Stawicki S., Jin Z., Wyatt S.K., Carano R.A., Zheng Y., Sweet-Cordero E.A., Wu Y., Jackson E.L. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci. Transl. Med. 2013, 5:171ra18.
16. Hettmann T., Schneider M., Ogbagabriel S., Xie J., Juan G., Hartmann S., Radinsky R., Freeman D.J. U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation. Cancer Res. 2010, 70:LB-306.
17. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer 2007, 97:453-457.
18. Jiang W., Freidlin B., Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl. Cancer Inst. 2007, 99:1036-1043.
19. Khleif S.N., Doroshow J.H., Hait W.N. AACR-FDA-NCI Cancer Biomarkers Collaborative, AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin. Cancer Res. 2010, 16:3299-3318.
20. Krane I.M., Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 1996, 12:1781-1788.
21. Liu J., Kern J.A. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am. J. Respir. Cell Mol. Biol. 2002, 27:306-313.
22. LoRusso P., Jänne P.A., Oliveira M., Rizvi N., Malburg L., Keedy V., Yee L., Copigneaux C., Hettmann T., Wu C.Y., Ang A., Halim A.B., Beckman R.A., Beaupre D., Berlin J. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2013, 19:3078-3087.
23. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
24. Mandrekar S.J., Sargent D.J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 2009, 27:4027-4034.
25. Mass R.D., Press M.F., Anderson S., Cobleigh M.A., Vogel C.L., Dybdal N., Leiberman G., Slamon D.J. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 2005, 6:240-246.
26. Motoyama A.B., Hynes N.E., Lane H.A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002, 62:3151-3158.
27. Müller-Tidow C., Diederichs S., Bulk E., Pohle T., Steffen B., Schwäble J., Plewka S., Thomas M., Metzger R., Schneider P.M., Brandts C.H., Berdel W.E., Serve H. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res. 2005, 65:1778-1782.
28. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
29. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
30. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13306-13311.
31. Patterson S.D., Cohen N., Karnoub M., Truter S.L., Emison E., Khambata-Ford S., Spear B., Ibia E., Sproule R., Barnes D., Bhathena A., Bristow M.R., Russell C., Wang D., Warner A., Westelinck A., Brian W., Snapir A., Franc M.A., Wong P., Shaw P.M. Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics 2011, 12:939-951.
32. Paz-Ares L., von Pawel J., Moritz B., Mendell J., Jin X., Copigneaux C., Beckman R. Phase (Ph) 3 study of patritumab (P) plus erlotinib (E) in EGFR wild-type subjects with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 2014, 25:iv426-iv470.
33. Polley M.Y., Freidlin B., Korn E.L., Conley B.A., Abrams J.S., McShane L.M. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J. Natl. Cancer Inst. 2013, 105:1677-1683.
34. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 1994, 13:2831-2841.
35. Sato Y., Yashiro M., Takakura N. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells. Cancer Sci. 2013, 104:1618-1625.
36. Schneider M., Blum S., Wenzl C., Bange J., Ogbagabriel S., Freeman D.J., Ruhe J. Heregulin expression level as a predictive biomarker for patritumab efficacy. J. Clin. Oncol. 2014, 32:2618.
37. Schoeberl B., Pace E.A., Fitzgerald J.B., Harms B.D., Xu L., Nie L., Linggi B., Kalra A., Paragas V., Bukhalid R., Grantcharova V., Kohli N., West K.A., Leszczyniecka M., Feldhaus M.J., Kudla A.J., Nielsen U.B. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2009, 2:ra31.
38. Schoeberl B., Faber A.C., Li D., Liang M.C., Crosby K., Onsum M., Burenkova O., Pace E., Walton Z., Nie L., Fulgham A., Song Y., Nielsen U.B., Engelman J.A., Wong K.K. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010, 70:2485-2494.
39. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., Joshi V.A., McCollum D., Evans T.L., Muzikansky A., Kuhlmann G.L., Han M., Goldberg J.S., Settleman J., Iafrate A.J., Engelman J.A., Haber D.A., Johnson B.E., Lynch T.J. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 2008, 26:2442-2449.
40. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
41. Shames D.S., Carbon J., Walter K., Jubb A.M., Kozlowski C., Januario T., Do A., Fu L., Xiao Y., Raja R., Jiang B., Malekafzali A., Stern H., Settleman J., Wilson T.R., Hampton G.M., Yauch R.L., Pirzkall A., Amler L.C. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS ONE 2013, 8:e56765.
42. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 2005, 23:7332-7341.
43. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 2009, 101:1446-1452.
44. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
45. Soltoff S.P., Carraway K.L., Prigent S.A., Gullick W.G., Cantley L.C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 1994, 14:3550-3558.
46. Treder M., Hartmann S., Ogbagabriel S., Borges E., Green L., Kang J., Radinsky R., Rothe M., Freeman D. Fully human anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo. AACR Meeting Abstracts 2008, LB-20.
47. Treder M., Ogbagabriel S., Moor R., Schulze-Horsel U., Hettmann T., Rothe M., Radinsky R., Freeman D. Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models. Eur. J. Cancer Suppl. 2008, 6:99.
48. Tsai M.S., Shamon-Taylor L.A., Mehmi I., Tang C.K., Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003, 22:761-768.
49. Ueno Y., Sakurai H., Tsunoda S., Choo M.K., Matsuo M., Koizumi K., Saiki I. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int. J. Cancer 2008, 123:340-347.
50. von Pawel J., Tseng J., Dediu M., Schumann C., Moritz B., Mendell-Harary J., Jin X., Feng W., Copigneaux C., Beckman R.A. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs). J. Clin. Oncol. 2014, 32:8045.
51. Wheeler D.L., Huang S., Kruser T.J., Nechrebecki M.M., Armstrong E.A., Benavente S., Gondi V., Hsu K.T., Harari P.M. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
52. Xia W., Gerard C.M., Liu L., Baudson N.M., Ory T.L., Spector N.L. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005, 24:6213-6221.
53. Xia W., Petricoin E.F., Zhao S., Liu L., Osada T., Cheng Q., Wulfkuhle J.D., Gwin W.R., Yang X., Gallagher R.I., Bacus S., Lyerly H.K., Spector N.L. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res. 2013, 15:R85.
54. Yang C.H., Yu C.J., Shih J.Y., Chang Y.C., Hu F.C., Tsai M.C., Chen K.Y., Lin Z.Z., Huang C.J., Shun C.T., Huang C.L., Bean J., Cheng A.L., Pao W., Yang P.C. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol. 2008, 26:2745-2753.
55. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
56. Yi E.S., Harclerode D., Gondo M., Stephenson M., Brown R.W., Younes M., Cagle P.T. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod. Pathol. 1997, 10:142-148.
57. Yonesaka K., Kawakami H., Kaneda H., Okamoto I., Hirotani K., Nishio K., Nakagawa K. The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer. J. Clin. Oncol. 2014, 32:e19082.
58. Zhou B.B., Peyton M., He B., Liu C., Girard L., Caudler E., Lo Y., Baribaud F., Mikami I., Reguart N., Yang G., Li Y., Yao W., Vaddi K., Gazdar A.F., Friedman S.M., Jablons D.M., Newton R.C., Fridman J.S., Minna J.D., Scherle P.A. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10:39-50.